Cybin Inc. announced the launch of its first strategic partnership agreement (SPA) with Segal Trials, aimed at supporting its multinational pivotal Phase 3 program for CYB003. This program is evaluating CYB003 for the adjunctive treatment of Major Depressive Disorder (MDD).
Segal Trials, the initial program member, operates a network of six research sites across South Florida and possesses extensive experience in psychiatry, neurology, addiction, and psychedelics research. This partnership is designed to facilitate collaboration among sites and enhance efficiency in trial operations.
The company intends to enroll approximately 550 patients across more than 40 clinical sites in the United States and Europe for the Phase 3 program. Engaging with leading clinical partners like Segal Trials is expected to advance the clinical program on an expedited basis, cultivating long-term partnerships and improving overall site performance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.